NFKB1 and mantle cell lymphoma: In MCL, the activity of bortezomib is primarily attributed to decreased proteasome degradation of inhibitor of kB (lkB) allowing continued inhibition over NF-κB pathway activity—a critical element in MCL tumorigenesis [46].